Henry Schein Q4 Earnings And Outlook Miss Expectations, Restructures For Growth

Core Insights - Henry Schein Inc. reported a fourth-quarter adjusted EPS of $1.19, an increase of 80.3$1.21 [1] - The company's sales reached $3.19 billion, reflecting a 5.8$3.30 billion [1] - Internal sales growth was 5.5%, with contributions from acquisitions at 0.7% and a decrease of 0.4% due to foreign currency exchange; excluding PPE and COVID test kits, internal sales growth was 6.6% [1] Financial Performance - The fourth-quarter results indicate stable dental and medical end-markets, with progress on the 2022 to 2024 BOLD+1 Strategic Plan, exceeding the 2024 target of generating 40% of worldwide operating income from high-growth, high-margin businesses [2] - The company has restructured into three segments, but analysts find it challenging to assess which segments underperformed, with expectations of continued weakness in the dental segment [3] Future Outlook - Henry Schein forecasts adjusted EPS for 2025 to be between $4.80 and$4.94, below the consensus of $5.01, with anticipated sales growth of approximately 2$10.8 billion in Global Distribution and Value-Added Services, $1.4 billion in Global Specialty Products, and$630 million in Global Technology [5]